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Objective: The authors conducted a randomized, double-blind, placebo-controlled trial of
intravenous versus oral pulse loading of clomipramine in patients with obsessive-compulsive
disorder to test two hypotheses: 1) intravenous pulse loading will cause greater immediate
improvement than oral pulse loading and 2) patients who respond to pulse loading will con-
tinue to improve during 8 weeks of oral clomipramine treatment. Method: Fifteen patients
with DSM-III-R obsessive-compulsive disorder of at least 1 year’s duration and baseline Yale-
Brown Obsessive Compulsive Scale scores of 17 or higher were enrolled in the study. Yale-
Brown scale ratings were made 4.5 days after double-blind oral or intravenous pulse loading
of clomipramine, and patients were then given 150 mg/day of oral clomipramine with increases
of 25 mg every 4 days to 250 mg/day as tolerated or, in two cases, other selective serotonin
reuptake inhibitors (SSRIs). Results: The first hypothesis was confirmed: 4.5 days after the
second pulse-loaded dose, six of seven patients given intravenous clomipramine but only one
of eight given oral medication responded to the drug. After 8 weeks of oral clomipramine, the
results partially supported the second hypothesis: four of six patients who had responded to
intravenous clomipramine continued their improvement, but those who had responded to
pulse loading did not improve statistically significantly more than those who had not. Con-
clusions: Intravenous pulse loading of clomipramine may be a valuable new treatment for
obsessive-compulsive disorder, particularly for patients who have failed oral treatment trials.
 (Am J Psychiatry 1997; 154:396–401)
O bsessive-compulsive disorder responds slowly toorally administered selective serotonin reuptake
inhibitors (SSRIs). For example, after 4 weeks of clomi-
pramine treatment, mean scores on the Yale-Brown
Obsessive Compulsive Scale (1) decreased by only
about 20% (2, 3). “Clinically meaningful improve-
ment” (a decrease of 35% or more) usually takes about
6 weeks to develop (4). Each available SSRI (clomipra-
mine, sertraline, fluoxetine, fluvoxamine, and paroxe-
tine) benefits about 45% to 60% of patients with ob-
sessive-compulsive disorder (5, 6). However, we cannot
predict which patient will respond to which drug or will
be unresponsive to all five drugs, and 8 to 10 weeks are
needed for each treatment trial (4, 7).
One SSRI, clomipramine, is available in intravenous
form. In Europe, intravenous clomipramine is commonly
used to treat obsessive-compulsive disorder and major
depression in both outpatients and inpatients (8–13).
Available data suggest that, in obsessive-compulsive
disorder, intravenously administered clomipramine re-
duces symptoms much more quickly than oral clomipra-
mine and is better tolerated. Warneke (14–16) reported
moderate to marked improvement in nine patients to-
ward the end of 14 daily infusions or shortly thereafter
and stated that about half of 30 patients with obsessive-
compulsive disorder experienced “moderate to marked
improvement.” Fallon et al. (17) reported a 39% aver-
age decrease in symptom scores in three of five patients
with obsessive-compulsive disorder after 14 consecu-
tive weekday infusions. Patients unable to tolerate ade-
quate doses of oral clomipramine easily tolerated intra-
venous clomipramine. In an earlier study (18), we
reported that five patients with obsessive-compulsive
disorder treated with gradually increased doses of intra-
venous clomipramine improved to a marked degree
within 4 weeks, i.e., almost twice as fast as in trials of
oral clomipramine. Sallee et al. (19) reported a decrease
of about 30% in obsessive-compulsive disorder symp-
tom scores in three adolescents within 36 hours of re-
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ceiving two infusions of clomipramine (75 mg and 200
mg) in 2 days. In addition, patients unresponsive to ade-
quate trials of oral clomipramine have subsequently
benefited from intravenous clomipramine (14, 17).
In view of these findings, we conducted a double-blind,
placebo-controlled trial of intravenous versus oral pulse
loading of clomipramine to test the following hypotheses:
1. Intravenous pulse loading of clomipramine (150 mg
on day 1 and 200 mg on day 2) will produce a marked
decrease in obsessive-compulsive disorder symptoms
within 4.5 days of the second dose, and this decrease will
exceed that produced by double-blind, oral pulse loading
of identical doses of clomipramine. We defined a
“marked decrease” as a 25% or greater decrease in Yale-
Brown scale score (7). Patients experiencing this decrease
are called “responders.”
2. Responders to pulse-loaded clomipramine will
maintain this benefit and will have improved more (as
measured by the Yale-Brown scale) after 8 weeks of
open-label oral clomipramine than nonresponders. That
is, the responders’ head start in symptom reduction will
keep their improvement ahead of that of nonresponders
for at least 2 months. Improvement will be measured
from the predrug baseline score.
METHOD
Patients
Eligible patients met DSM-III-R criteria for obsessive-compulsive
disorder based on Structured Clinical Interview for DSM-III-R (20)
results, had been ill for at least 1 year, and had a minimum Yale-
Brown scale score of 17. Patients with DSM-III-R major depression
were eligible if the depression began after the obsessive-compulsive
disorder and obsessive-compulsive disorder was the primary diagno-
sis, strongly dominating the clinical picture. After the study had been
explained to them, all study subjects gave written informed consent.
For subjects aged 18 or younger, we obtained written informed con-
sent from both parent and child.
Study exclusion criteria were age less than 15 or more than 50 years;
pregnant, nursing, or of childbearing potential and not using an effective
contraceptive method; a history of schizophrenia, bipolar disorder,
posttraumatic stress disorder, borderline personality disorder, or ano-
rexia; IQ less than 70; drug or alcohol abuse or dependence within the
past 6 months; a history of clinically significant, severe adverse reactions
to clomipramine; a history or evidence of clinically significant physical
or laboratory abnormality, medical disease, risk factors for seizure dis-
order, or medical contraindications to treatment with tricyclic anti-
depressant drugs; exposure to ECT, a monoamine oxidase inhibitor
within 4 weeks, a depot neuroleptic or fluoxetine within 6 weeks, or any
other regular, daily psychotropic or corticosteroid (except topical)
within 2 weeks of starting clomipramine.
Clomipramine Dose and Administration
Clomipramine for intravenous administration is manufactured by
CIBA-GEIGY and distributed in Europe and Asia. The drug vials con-
tain 25 mg of clomipramine, 54 mg of glycerine as an excipient, and 2
ml of distilled water. We obtained and administered intravenous clomi-
pramine under Investigational New Drug permit number 36,784. Hos-
pital pharmacists prepared materials for double-blind administration.
Patients were randomly assigned to either intravenous or oral
pulse-loaded clomipramine. They were admitted to an inpatient re-
search unit the night before clomipramine administration. The fol-
lowing morning at 9:00 a.m. they received an intravenous test dose
of 12.5 mg of clomipramine in normal saline for neuroendocrine
studies to be reported elsewhere. Double-blind, placebo-controlled
pulse loading of clomipramine began at 6:30 p.m. that evening, pre-
ceded by oral administration of 250 mg of trimethobenzamide hydro-
chloride to reduce nausea. On day 1, over 90 minutes, patients re-
ceived double-blind either 150 mg of intravenous clomipramine in
500 mg of normal saline or normal saline alone (placebo) (19). As
the infusion began, patients took double-blind oral doses of 150 mg
of clomipramine or of placebo. Cardiac monitoring was in place
throughout the infusion period and for 30 minutes afterward. Nurs-
ing staff monitored vital signs and side effect complaints every 15
minutes during the infusions and every 30 minutes for 2 hours after-
ward; during this time patients remained at bed rest. The infusion
procedure was repeated 24 hours later with 200 mg of clomipramine
(or normal saline) and 200 mg of oral clomipramine (or placebo). The
patient was discharged from the inpatient unit the following morning.
Patients previously unable to tolerate oral clomipramine were al-
lowed to enroll in the study because the experience of others sug-
gested that such patients tolerate and usually benefit from intrave-
nous clomipramine (14, 17).
Following the method of Pollock et al. (21), we gave oral clomipra-
mine to the patients 4.5 days after the second pulse-loaded dose. The
starting dose was 150 mg, increased by 25 mg every fourth day to 250
mg/day as tolerated (17).
Laboratory Methods
We obtained a blood sample immediately after the second pulse-
loaded infusion to assay peak plasma levels of clomipramine and des-
methylclomipramine. These levels were not substantially affected by
the first morning’s 12.5-mg challenge dose. Clomipramine has a half-
life of about 40 hours (21), but clomipramine levels are only about
20 ng/ml and desmethylclomipramine levels are not detectable 3
hours after a 10-mg intravenous dose of clomipramine (22).
Clomipramine and desmethylclomipramine levels were determined
by using a normal-phase high performance liquid chromatography
method with a lower limit of quantitation of 1 ng/ml. Extraction recov-
eries typically range from 90% to 101%. Within- and between-day co-
efficients of variation range from 1.6% to 12.1% (23).
Efficacy and Safety Evaluation
We rated patients’ symptoms with the 10-item Yale-Brown scale
and the 17-item Hamilton Depression Rating Scale (24). Ratings took
place immediately before the infusion of 150 mg of clomipramine (or
saline) and 4.5 days after the infusion of 200 mg of clomipramine (or
saline). The investigators were blind to whether patients had received
intravenous or oral clomipramine.
Beginning 4.5 days after the second infusion, patients were seen
weekly for 4 weeks and again at the end of week 8, when the trial
ended. At each visit, we recorded the patient’s blood pressure and
pulse, inquired about adverse events, and rated obsessive-compulsive
disorder symptoms.
Statistical Methods
We used Student’s t test, two-tailed, to look for significant demo-
graphic and clinical differences between the two treatment groups at
baseline and to test for differences in Yale-Brown scale scores at base-
line, day 4.5, and after 8 weeks of oral clomipramine treatment. We
used Fisher’s exact test to test whether the group receiving intrave-
nous medication was more likely than the group receiving oral medi-
cation to experience a 25% or greater decrease in Yale-Brown scale
score at day 4.5. We used the Spearman rank correlation to look for
a linear relationship between peak plasma clomipramine levels and
change in Yale-Brown scale scores at day 4.5.
RESULTS
We enrolled 15 patients: seven were randomly assigned
to intravenously pulse-loaded clomipramine and eight
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to orally pulse-loaded clomipramine. There were no sta-
tistically significant differences between the two groups
in mean age, duration of illness, number who had failed
previous adequate trials of oral clomipramine, mean
baseline Yale-Brown scale score (and range), or mean
baseline Hamilton depression scale score (table 1). In
the group receiving intravenous medication, three pa-
tients had comorbid major depression, one had comor-
bid dysthymia, and one had comorbid panic disorder.
The immediate outcome was consistent with our first
hypothesis: 4.5 days after the second pulse-loaded dose
of clomipramine, six of the seven patients given intrave-
nous clomipramine experienced a marked response (i.e.,
a 25% or greater decrease in Yale-Brown scale score).
The mean decrease in Yale-Brown scale score for the six
patients was 40.8% (range=26.3%–55.5%) (table 2).
Only one of the eight patients receiving oral clomipra-
mine experienced a marked response (p=0.009, one-
tailed Fisher’s exact test). Further, the mean Yale-Brown
scale score at day 4.5 of the group given intravenous
pulse loading (mean=16.7, SD=3.3) was statistically sig-
nificantly lower than that of the group given oral pulse
loading (mean=25.0, SD=7.9) (independent samples
t=2.59, df= 13, pooled variance, p=0.02).
Unfortunately, peak plasma clomipramine and des-
methylclomipramine levels were available for only six of
the seven patients receiving double-blind intravenous
pulse loading and only one of the eight patients receiving
double-blind oral pulse loading. The peak plasma levels
of the patients given intravenous pulse loading were four
to 14 times higher than the level of the patient given oral
pulse loading. The peak plasma clomipramine level and
the percent decrease in Yale-Brown scale scores (table 2)
were not statistically significantly correlated (rs=0.39,
N=7) (for p=0.05, rs must reach 0.71). Moreover, the sin-
gle nonresponder to intravenous pulse loading
had the second highest peak plasma clomipra-
mine level (table 2).
After 8 weeks of oral clomipramine treatment,
our second hypothesis was only partially sup-
ported (table 2). Four of the six patients who
were responders to intravenous clomipramine
at day 4.5 maintained or increased their im-
provement (mean decrease in Yale-Brown scale
score from predrug baseline=59%, range=39%–
74%). One responder to intravenous clomipra-
mine permanently lost the response after 1 week
of oral treatment, and one partially lost the re-
sponse and dropped out at week 4 of oral clomi-
pramine treatment because of discouragement.
Two patients who were nonresponders to a pre-
vious adequate trial of oral clomipramine were
responders at both day 4.5 and after 8 weeks of
oral treatment. The other two patients given in-
travenous medication who had been unrespon-
sive to oral clomipramine were nonresponders
after 8 weeks of oral clomipramine treatment.
Interestingly, these two patients had the highest
peak plasma clomipramine levels.
In the group given oral pulse loading, the only
responder at 4.5 days (patient 8) refused oral clomipra-
mine because he had previously tolerated it poorly and
without much benefit (table 2). He improved further on
150 mg/day of sertraline. Patient 12, having failed an
adequate trial of clomipramine, also refused oral clomi-
pramine maintenance and was treated with 80 mg/day of
paroxetine but did not respond. After 8 weeks of oral
clomipramine treatment, the seven patients who were
nonresponders on day 4.5 of oral pulse loading had vary-
ing outcomes: three achieved a 25% or greater decrease
in Yale-Brown scale score (range=28%–84%); two re-
mained nonresponders; and two dropped out. Patient 14,
having failed a previous adequate trial of clomipramine,
refused oral clomipramine maintenance after experienc-
ing “absolutely no change” at day 4.5. He later failed to
benefit from open-label intravenous pulse loading of
clomipramine, with a peak plasma clomipramine level of
182 ng/ml. Patient 15 dropped out because her obses-
sive-compulsive disorder worsened; she subsequently
responded to open-label intravenous pulse loading of
clomipramine.
Contrary to our second hypothesis, last-observation-
carried-forward analysis revealed no statistically sig-
nificant difference between mean Yale-Brown scale
scores after 8 weeks of oral clomipramine treatment of
the seven patients who were responders (mean=15.6,
SD=9.9) and the eight nonresponders (mean=20.5, SD=
11.1) on day 4.5 of pulse loading (independent samples
t=0.90, df=13, pooled variance, p=0.38). Note that in
the groups given intravenous and oral pulse loading,
the proportion of responders after 8 weeks of oral clo-
mipramine treatment was similar: four (57%) of seven
patients given intravenous pulse loading and four
(50%) of eight patients given oral pulse loading.
Comorbid depression often, but not always, improved
TABLE 1. Characteristics of Patients With Obsessive-Compulsive Disorder Re-






Mean SD Mean SD
Age (years) 33.4 4.3 29.1  4.3
Duration of illness (years) 12.6 9.1 14.1 14.6
Baseline Yale-Brown Obsessive
Compulsive Scale score 27.7 7.4 25.9  5.5
Baseline 17-item Hamilton De-




Onset before age 18 4 8
Failed an oral clomipramine triala 4 4
Failed two or more selective sero-
tonin reuptake inhibitor trials 5 5
Failed three or more selective se-
rotonin reuptake inhibitor trials 5 3
Comorbid major depression 3 2
a≥200 mg/day of clomipramine for ≥8 weeks.
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along with improvement in obsessive-compulsive disor-
der. At day 4.5, the obsessive-compulsive symptoms of
all three patients given intravenous clomipramine who
had comorbid depression improved, but only two expe-
rienced diminished depression (Hamilton depression
scale decreases of 29% and 66%). In the group receiving
oral medication, both the obsessive-compulsive disorder
and the depression of one patient improved (Hamilton
depression scale score decreased by 32%); the other ex-
perienced no improvement in either condition (Hamilton
depression scale score increased by 30%). After 8 weeks
of oral clomipramine treatment, the pattern of results
continued unchanged in the group given intravenous
pulse loading (the two depressions remitted); in the group
given oral pulse loading, the day 4.5 double responder
had continued improvement in obsessive-compulsive dis-
order and remission of depression, but the day-4.5 obses-
sive-compulsive disorder nonresponder had remission of
depression at the end of week 4 of clomipramine treat-
ment but still had no response in obsessive-compulsive
disorder. The patient with comorbid dysthymia, who re-
ceived intravenous clomipramine, experienced no improve-
ment in obsessive-compulsive disorder or dysthymia.
Two patients experienced troubling adverse events.
One patient, who had a past history of panic disorder,
experienced a panic attack and mild dystonia after the
double-blind infusion of 150 mg of clomipramine and
declined the second infusion. She nonetheless was a re-
sponder at day 4.5. The second patient became hypo-
tensive and bradycardic about 10 minutes after the sec-
ond double-blind infusion (200 mg of clomipramine)
ended, while the nurse was drawing blood for a plasma
level. This may have been an anxiety-induced vasovagal
attack, since the patient later said that he had been quite
worried when the nurse had difficulty obtaining his
blood sample. His symptoms responded rapidly to 0.5
mg of intravenous atropine and volume expansion with
500 ml of normal saline.
During pulse loading, three of seven patients given in-
travenous clomipramine had no side effects. The other
four, including the two with the adverse events just de-
scribed, had mild side effects, including nausea (N=3),
dizziness (N=2), dry mouth (N=2), sweating (N=2), rest-
lessness (N=1), flushing (N=1), drowsiness (N=1), rest-
less sleep (N=1), and polyuria (N=1). Three of the eight
patients given oral clomipramine had no side effects. The
other five had mild side effects, including nausea (N=3),
sweating (N=1), drowsiness (N=1), fatigue (N=1), ab-
dominal distress (N=1), and nervousness (N=2).
DISCUSSION
Although limited by a small number of patients, our
double-blind, placebo-controlled study results clearly
suggest that pulse loading of intravenous clomipramine
produces a large and rapid decrease in obsessive-com-
pulsive disorder symptoms and that oral pulse loading
does not. The four- to 14-times higher peak plasma clo-
mipramine levels in the group receiving intravenous medi-
cation than in the one patient given oral medication
begin to suggest that the greater efficacy of intravenous
TABLE 2. Yale-Brown Obsessive Compulsive Scale Scores and Serum Clomipramine and Desmethylclomipramine Levels in Patients With





Peak Serum Level (ng/ml) Week of
Desmethyl- Day
Oral Clomipramine Treatment
Patient Clomipramine clomipramine Baseline 4.5 1 2 4 8 Day 4.5
Patients given intravenous
clomipramine
 1a 232 10 36 16 20  5 10 10 55.5 
 2a 667 15 36 20 30 29 32 35 44.4 
 3 — — 31 18  6 — 10 15 41.9 
 4 288 10 18 11 — 15 15 —b 38.9 
 5a 241 10 29 18 19 20 20 20 37.9 
 6 211  8 19 14 13 11 10  5 26.3 
 7a 507  9 25 20 27 27 22 28 20.0 
Patients given oral
clomipramine
 8c — — 25 17 20 20 —  9 32.0 
 9 — — 17 14 14 16 17 17 17.6 
10a 48 18 29 27 24 21 17 21  6.9 
11 — — 25 24 —  6 —  4  4.0 
12a,d — — 19 19 — — 18 15  0.0 
13 — — 35 35 32 28 23 11  0.0 
14 — — 30 30 30 —b —b —b  0.0 
15 — — 27 34 33 38 —b —b (25.9)e
aFailed a previous adequate trial of oral clomipramine.
bDropped out.
cTolerated poorly without benefit 150 mg/day oral clomipramine in previous trial; maintenance treatment was oral sertraline, 150 mg/day.
dAlso failed previous adequate trials of fluoxetine and sertraline; maintenance treatment was oral paroxetine, 80 mg/day.
eScore increased rather than decreased.
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clomipramine may be related to rapid attainment of
high plasma levels. The mean plasma clomipramine
level 8 to 10 hours after intravenous pulse loading (mean=
171 ng/ml, SD=50) (21) is indistinguishable from that
seen after 12 weeks of oral clomipramine at a maxi-
mum stable dose of 239.4 mg/day (SD=57.0) (mean=
169.9 ng/ml, SD=102.1) (25).
Our results stand in contrast to those observed in ma-
jor depression. Oral pulse loading of imipramine pro-
duces a dramatic response within 72 hours (26), but
intravenous pulse loading of clomipramine does not
produce a faster or larger response than oral pulse load-
ing (21). Given that the groups receiving oral and intra-
venous medications in that study achieved mean plasma
clomipramine levels in excess of 100 ng/ml, perhaps
most patients in both groups exceeded a threshold level
required for an antidepressant effect. That threshold
may be higher in obsessive-compulsive disorder, in view
of the often-voiced clinical opinion that higher SSRI
doses are needed to treat obsessive-compulsive disorder
than to treat major depression (4).
In obsessive-compulsive disorder, the rapidity of symp-
tom relief induced by intravenous pulse loading far ex-
ceeds that induced by oral pulse loading or standard oral
dosing regimens (2, 3). This result cannot be explained
by the “drama” associated with intravenous lines, car-
diac monitors, and inpatient admission because our dou-
ble-blind study design assured that the group given oral
pulse loading experienced the same drama.
Pulse loading of intravenous clomipramine also im-
proves obsessive-compulsive disorder symptoms faster
than gradually escalated intravenous dosing of clomipra-
mine. In an open-label study, six of seven patients receiv-
ing pulse-loaded doses but none of 20 patients receiving
gradually escalated intravenous doses had marked de-
creases in obsessive-compulsive disorder symptoms at
day 4.5 (unpublished data of L.M.K. et al.).
Two of the four patients who had been nonrespon-
ders to adequate previous trials of oral clomipramine
responded during and after intravenous clomipramine
pulse loading. Our experience with these patients ech-
oes the observations of Warneke (14) and Fallon et al.
(17), who used open-label, gradually escalated doses of
intravenous clomipramine.
Most responders to intravenous pulse loading im-
proved further when switched to oral clomipramine.
One permanently lost the early response, and one par-
tially lost the response and discontinued clomipramine
treatment. Whether the lost or diminished therapeutic
effect was related to the lower serum clomipramine lev-
els produced by oral dosing deserves study. Although
the mean Yale-Brown scale scores after 8 weeks of oral
clomipramine treatment of the patients who were or
were not responders at day 4.5 of pulse loading were
not statistically significantly different, the difference (5
points on the Yale-Brown scale, representing about
one-half of a standard deviation) appears clinically
meaningful; the absence of statistical significance may
reflect low statistical power because of the small num-
ber of patients in our study.
The improvement in obsessive-compulsive disorder
in our patients with and without comorbid depression
is consistent with the finding that oral clomipramine is
effective in nondepressed patients with obsessive-com-
pulsive disorder (2).
Five of the seven patients given intravenous clomipra-
mine had only minor side effects. The panic attack expe-
rienced by one patient is not a contraindication to intra-
venous clomipramine in patients with histories of panic;
the likelihood of this reaction is unknown. The instance
of hypotension and bradycardia together with reports of
cardiovascular side effects of intravenous clomipramine
(8, 13) suggest that careful cardiovascular monitoring is
indicated during intravenous clomipramine infusions. In
our opinion, pulse loading of intravenous clomipramine
is contraindicated for patients with heart disease, a his-
tory of severe adverse reactions to oral clomipramine,
risk factors for seizure disorder, or medical contraindica-
tions to treatment with tricyclic antidepressants.
We can only speculate on the neurophysiological
mechanisms underlying the rapid response to intrave-
nous clomipramine pulse loading because the patho-
physiology of obsessive-compulsive disorder remains
poorly understood. We know that intravenous pulse
loading, by avoiding first-pass liver metabolism,
achieves higher serum clomipramine levels, and presum-
ably higher brain concentrations, than does oral pulse
loading (21).
Clomipramine is a potent inhibitor of serotonin reup-
take and penetrates the blood-brain barrier easily. Con-
centrations in the brain are 10 times those in plasma after
a single parenteral dose (27). Could higher brain concen-
trations explain why some nonresponders to oral clomi-
pramine respond to intravenous clomipramine? Given
the evidence suggesting that the pathophysiology of ob-
sessive-compulsive disorder involves deficient serotonin
neurotransmission (28), we may speculate that the higher
brain concentrations of clomipramine achieved by intra-
venous pulse loading either lead to rapid desensitization
of serotonergic receptors or initiate changes in postsy-
naptic serotonergic neurons (G-protein signal transduc-
tion, cyclase and phosphatidylinositol second messen-
ger activity, or gene expression) that usually can be
maintained by oral clomipramine.
Tricyclic antidepressants related to clomipramine can
affect gene expression in the brain. For example, desip-
ramine increases hypothalamic glucocorticoid receptor
mRNA (29), and imipramine decreases tyrosine hy-
droxylase mRNA in the locus ceruleus (30). In rats,
however, the levels of mRNAs encoding serotonergic
receptors, their synthetic enzymes, and the 5-HT trans-
porter are not affected by up to 1 month of treatment
with tricyclic or SSRI antidepressants (31). Still, the high
brain tissue levels of clomipramine rapidly achieved by
intravenous pulse loading may more strongly affect the
expression of genes involved in obsessive-compulsive
disorder’s pathophysiology than do the brain levels as-
sociated with standard oral dosing.
Larger-scale, double-blind trials are needed to con-
firm our observations regarding the effects of intrave-
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nous clomipramine pulse loading. To examine further
the possible relationship between therapeutic response
and plasma clomipramine levels, peak and subsequent
plasma levels of clomipramine, 8-OH clomipramine
(32), desmethylclomipramine, and 8-OH desmethyl-
clomipramine should be obtained for all patients. If our
therapeutic results are confirmed, then intravenous
clomipramine pulse loading would be a valuable new
treatment for obsessive-compulsive disorder. First, this
method appears to save months of waiting to see whether
clomipramine will be effective, since those who ulti-
mately benefit almost always experience substantial
therapeutic response within 5 days of the second infu-
sion. Second, patients unresponsive to oral clomipra-
mine and other SSRIs seem to have about a 50% chance
of responding to intravenous clomipramine pulse load-
ing. Third, if patients rapidly improve after two intra-
venous infusions, their motivation to cooperate with
further treatment would be greatly enhanced.
Since some patients have difficulty tolerating oral clo-
mipramine (3), future research might profitably inves-
tigate whether a response to intravenous clomipramine
pulse loading can be maintained by oral doses of SSRIs
with different side effect profiles.
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